Insight

Timing of Toxicities and Mortality Following CAR T Therapy in Myeloma

Photo from Nausheen Ahmed/X

Jul 28, 2024, 15:37

Timing of Toxicities and Mortality Following CAR T Therapy in Myeloma

Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center, shared a post on X:

“Timing of Toxicities and Non-Relapse Mortality Following Chimeric antigen receptor (CAR) T Therapy in Myeloma by the Nausheen Ahmed, KU Cancer Center.

Things to Know:

New-onset Cytokine Release Syndrome (CRS)/Immune effector Cell–Associated Neurotoxicity Syndrome (ICANS) are rare after 2 weeks from Idecabtagene Vicleucel
and Ciltacabtagene Autoleucel infusion.
Early Non Relapse Mortality (NRM), <30 days is driven by Immune E-associated HLH-like Syndrome (IEC-HS) and infection.
Late NRM (30-90 days) is driven by infection.
Flexible Risk Evaluation and Mitigation Strategy (REMS) monitoring period partnering with local oncologists may be safe.”

Source: Al-Ola A Abdallah/X

Al-Ola A Abdallah cancer CAR T therapies Ciltacabtagene Autoleucel Cytokine Release Syndrome (CRS) idecabtagene vicleucel immune effector cell-associated HLH-like syndrome (IEC-HS) Immune effector Cell–Associated Neurotoxicity Syndrome (ICANS) KU Cancer Center Myeloma Nausheen Ahmed Non Relapse Mortality (NRM) OncoDaily Oncology Risk Evaluation and Mitigation Strategy (REMS)

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage